IBM teams with Italian institute to test biomed analytics platform
IBM has developed a biomedical analytics platform for personalized medicine that could enable better clinical decision support.
Scientists from IBM Research are collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori, a research and treatment cancer center in Milan, on the new decision support tool. The analytics platform is being tested by the institute's physicians to personalize treatment based on automated interpretation of pathology guidelines and intelligence from past clinical cases, documented in the hospital information system.
The tool, Clinical Genomics, can integrate and analyze all available clinical knowledge and guidelines, and correlate it with available patient data to create evidence that supports a specific course of treatment for each patient, according to IBM.
In addition to supporting decision-making about treatment, it can provide administrators at the institute with an aggregated view of patient care, enabling them to evaluate performances, IBM added.
Scientists from IBM Research are collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori, a research and treatment cancer center in Milan, on the new decision support tool. The analytics platform is being tested by the institute's physicians to personalize treatment based on automated interpretation of pathology guidelines and intelligence from past clinical cases, documented in the hospital information system.
The tool, Clinical Genomics, can integrate and analyze all available clinical knowledge and guidelines, and correlate it with available patient data to create evidence that supports a specific course of treatment for each patient, according to IBM.
In addition to supporting decision-making about treatment, it can provide administrators at the institute with an aggregated view of patient care, enabling them to evaluate performances, IBM added.